BioMarin will stop dosing some patients in two of its mid-stage studies for Voxzogo after a hip-related safety concern was flagged in two independent trials.
The process by which institutional review boards oversee clinical trials needs reforms that are “big and different” so that the US can keep pace with
Plus, news about Bayer’s Kerendia, Eli Lilly’s Ebglyss and Alto Neuroscience: 📈 CytomX’s colorectal cancer data: The biotech tested multiple doses of its antibody-drug conjugate
A maternal care startup offering virtual and in-person care just raised $12 million in new funding after dropping commercial insurers to focus on Medicaid, Endpoints
AstraZeneca’s cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage gastric cancer.
Ultragenyx said its gene therapy candidate for a rare metabolic disease has hit one of two primary endpoints in a late-stage study.
The drug is being tested in 37 people with ornithine transcarbamylase deficiency, a …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844